Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krystal, G. W.
Right arrow Articles by Buchdunger, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krystal, G. W.
Right arrow Articles by Buchdunger, E.
Clinical Cancer Research Vol. 6, 3319-3326, August 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth1

Geoffrey W. Krystal2, Sittisak Honsawek, Julie Litz and Elisabeth Buchdunger

Department of Medicine, Division of Hematology/Oncology [G. W. K., J. L.], and Department of Microbiology/Immunology [G. W. K., S. H.], Virginia Commonwealth University, McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, and Oncology Research Department, Novartis International, Inc., CH 4002, Basel, Switzerland [E. B.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
At least 70% of small cell lung cancers express the Kit receptor tyrosine kinase and its ligand, stem cell factor (SCF). Numerous lines of evidence have demonstrated that this coexpression constitutes a functional autocrine loop, suggesting that inhibitors of Kit tyrosine kinase activity could have therapeutic efficacy in this disease. STI571, formerly known as CGP 57148B, is a p.o. bioavailable 2-phenylaminopyrimide derivative that was designed as an Abl tyrosine kinase inhibitor, but also has efficacy against the platelet-derived growth factor receptor and Kit in vitro. Pretreatment of the H526 small cell lung cancer (SCLC) cell line with STI571 inhibited SCF-mediated Kit activation with an IC50 of 0.1 µM as measured by inhibition of receptor tyrosine phosphorylation and 0.2 µM as measured by immune complex kinase assay. This paralleled the inhibition of SCF-mediated growth by STI571, which had an IC50 of ~0.3 µM. Growth inhibition in SCF-containing medium was accompanied by induction of apoptosis. STI571 efficiently blocked SCF-mediated activation of mitogen-activated protein kinase and Akt, but did not affect insulin-like growth factor-1 or serum-mediated mitogen-activated protein kinase or Akt activation. Growth of five of six SCLC cell lines in medium containing 10% FCS was inhibited by STI571 with an IC50 of ~5 µM. Growth inhibition in serum-containing medium appeared to be cytostatic in nature because no increase in apoptosis was observed. Despite this growth inhibition, STI571 failed to enhance the cytotoxicity of either carboplatinum or etoposide when coadministered. However, taken together with the minimal toxicity that this compound has shown in preclinical studies, these data suggest that STI571 could have a role in the treatment of SCLC, possibly to block or slow recurrence after chemotherapy-induced remissions.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein tyrosine kinases play a critical role in intracellular signal transduction pathways leading to diverse cellular responses, such as proliferation, apoptosis, and differentiation (1 , 2) . Consequently, these enzymes have become primary targets for the development of novel therapeutics designed to block cancer cell proliferation, metastasis, angiogenesis, and promote apoptosis (3 , 4) . The strategy that has progressed farthest in clinical development is the use of monoclonal antibodies to target growth factor receptor tyrosine kinases (5) . The use of small molecule tyrosine kinase inhibitors, however, could have significant theoretical advantages over monoclonal antibodies. Small molecule inhibitors could have better tissue penetration, could have activity against intracellular targets, and could be designed to have oral bioavailability. Their interaction with the target enzyme can be more easily studied through the use of X-ray crystallography and computer modeling, and their structure could be more easily engineered to give the drug more specificity and more favorable pharmacokinetic properties. Several lead compounds have shown promising activity against such targets as the EGFR3 (6 , 7) and the vascular endothelial cell growth factor receptor (8) .

The compound STI571 (formerly known as CGP 57148B) is a 2-phenylaminopyrimide derivative that was optimized for selective inhibition of the Bcr-Abl tyrosine kinase (9 , 10) , which is a fusion protein that results from the pathogenic 9:22 translocation that occurs in 95% of CML (11) . The drug showed a cellular IC50 for inhibition of Bcr-Abl kinase activity of ~0.25 µM and inhibited growth of cell lines engineered to be dependent on Bcr-Abl kinase activity at 1 µM (10 , 12) . In addition, STI571 also selectively inhibited the growth of continuous cell lines derived from CML patients, as well as primary CML progenitors in clonogenic assays, at low micromolar concentrations (10 , 13 , 14) . Recently, it has been demonstrated that the drug, given at pharmacokinetically appropriate doses, can completely block the outgrowth of CML cells in nude mice xenografts and cause complete regression of the majority of established tumors with oral dosing without detectable systemic toxicity (15) . Although STI571 appears to be a potentially exciting new treatment for CML patients not curable with allogeneic bone marrow transplantation (16) , it could also be potentially useful for the treatment of other malignancies. This is attributable to the fact that although STI571 is highly selective for Bcr-Abl and c-Abl versus most other tyrosine kinases, it does inhibit the PDGFR with similar efficacy to Bcr-Abl (12) . Preliminary evidence also suggests that the drug can also inhibit the Kit receptor tyrosine kinase in vitro.4 This cross-inhibition is likely secondary to a conserved structure of the ATP-binding pocket, the site of drug interaction, among these kinases. Thus, we hypothesized that STI571 might also be effective against malignancies in which Kit activation plays an important role.

The Kit growth factor receptor tyrosine kinase is in the same subclass as the receptors for platelet-derived growth factor and colony-stimulating factor-1 (17) . Kit’s ligand is SCF (alternatively named mast cell growth factor or steel factor), a hemopoietic growth factor that, in conjunction with other hemopoietic growth factors, supports the proliferation and differentiation of multiple hemopoietic cell lineages from early precursors (18) . In addition to hemopoietic cells, Kit is also normally expressed in melanocytes and germ cells, as well as in a variety of hematological malignancies and solid tumors, including SCLC. In fact, >70% of SCLC cell lines and tumor specimens coexpress Kit and its ligand, SCF (19, 20, 21) , leading to the hypothesis that this coexpression constitutes an autocrine growth loop. Evidence supporting a SCF/Kit autocrine loop includes the observation that growth and chemotaxis of selected SCLC cell lines is stimulated by exogenous SCF (22 , 23) . In addition, we demonstrated that reconstitution of SCF and Kit coexpression in a SCLC cell line led to enhanced growth factor independence, and inhibition of Kit activation by transfection of a dominant-negative c-kit gene resulted in a loss of growth factor independence (23 , 24) . Furthermore, the quinoxaline tyrphostin AG 1296, an inhibitor of Kit and the PDGFR, completely blocked SCF-dependent growth of the H526 cell line and promoted apoptosis within 48 h (23) . Treatment of a representative panel of SCLC cell lines grown in FCS with an optimal concentration of AG 1296 led to growth inhibition averaging ~50% in five of six responding cell lines. The use of AG 1296, however, is limited by is poor solubility in aqueous solution. The purpose of the present study was to determine whether the more soluble and p.o. bioavailable STI571 would inhibit SCF-dependent Kit activation and growth of SCLC cell lines.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Growth.
SCLC cell lines were grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, with (complete medium) or without 10% fetal bovine serum (Life Technologies, Gaithersburg, MD); when grown in the absence of serum, 0.1% BSA (Sigma, St. Louis, MO) was added to the medium. Where indicated, serum-free medium was supplemented with recombinant SCF (Intergen, Purchase, NY) or IGF-1 (R&D, Minneapolis, MN) at the indicated concentrations. The H146, H209, H432, H510, and H526 cell lines have been previously characterized by Carney et al. (25) . The WBA cell line was grown from the involved bone marrow aspirate of an untreated patient, and it coexpresses SCF and Kit, as well as N-myc (20) . Cells were stimulated with SCF and IGF-1 after preincubation in serum-free medium overnight. Cell growth was measured using the MTT (Sigma) colorimetric dye reduction method, an assay shown to correlate very well with viable SCLC cell number under the conditions used (26) . Duplicate plates containing eight replicate wells per assay condition were seeded at a density of 1 x 104 cells in 0.1 ml of medium, and data were expressed as the change in absorbance at 540 nM over 72 h, relative to initial values obtained 3 h after plating. STI571 was solubilized in DMSO; final concentration of DMSO in all cultures, including controls, was 0.1%. Stock solutions of carboplatinum (kindly provided by Bristol Myers Squib, Princeton, NJ) and etoposide (Calbiochem, San Diego, CA) were also made up at 1000-fold the desired final concentration in H2O and DMSO, respectively.

Assays for Apoptosis and Tritiated Thymidine Incorporation.
DNA fragmentation was analyzed using the TUNEL technique (27) , which was performed with the In Situ Cell Death Detection Kit (Boehringer-Mannheim, Indianapolis, IN) using the protocol supplied by the manufacturer. Fluorescence was quantitated using a Becton Dickinson FACScan flow cytometer with the FACScan research software package; nuclear labeling was confirmed by fluorescence microscopy. Caspase-3 activity was determined using the CaspACE assay system (Promega, Madison, WI). Briefly, after a 48-h incubation under the indicated conditions, cell pellets were resuspended in cell lysis buffer at a concentration of 108 cells/ml. To achieve cell lysis, cells were frozen at -80°C overnight, thawed, and incubated on ice for 15 min. Lysates were cleared by centrifugation at 15,000 x g for 20 min in the cold, and 500 µg of supernatant protein were used for the colorimetric assay exactly as described in the manufacturer’s protocol. Tritiated thymidine incorporation was determined after plating 2 x 104 cells in eight replicate wells of a microplate dish containing 0.1 ml of medium to which 1 µCi of tritiated thymidine (DuPont NEN, Boston, MA) had been added. Cells were then transferred to glass fiber filter plates using an automated cell harvester (Packard Instruments, Meridian CT), extensively washed with H2O, and counted using a liquid scintillation counter.

IP, Immune Complex Kinase Assay, and Western Blotting.
H526 cells were lysed in a buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% NP40, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 0.2 mM NaVO4, 100 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and 10 µg/ml leupeptin using a Dounce homogenizer with a tight-fitting pestle; protein concentrations were determined by bicinchoninic acid assay (Pierce, Rockford, IL). The lysate, containing 1–1.5 mg of protein, was centrifuged for 10 min at 10,000 x g to obtain a soluble postnuclear supernatant. IP was initiated by the addition of 10 µg of monoclonal anti-Kit antibody (K45; NeoMarkers, Fremont, CA), followed by incubation for 2 h at 4°C and by an additional 2 h in the presence of Protein A+G agarose. The IP was washed four times in lysis buffer and then once in PBS. The pellet was aspirated to dryness, and 30 µl of kinase buffer (20 mM 1,4-piperazinediethanesulfonic acid, 10 mM MnCl2) containing 0.1 µM [{gamma}-P32]ATP (3000 Ci/mmol; DuPont NEN) was added. The kinase reaction was carried out for 10 min at room temperature and terminated by the addition of an equal volume of 2x SDS sample loading buffer; the reaction was then resolved on a 10% polyacrylamide gel and analyzed by autoradiography. Western blotting was performed using standard procedures, with detection using the enhanced chemiluminescence system (Amersham, Arlington Heights, IL). Staining was accomplished using the following antibodies: anti-Kit, 3D6 monoclonal (Boehringer-Mannheim); antiphosphotyrosine, PY20 monoclonal (Transduction Labs, Lexington, KY); antiactive MAP kinase polyclonal (Promega); anti-phospho-Akt Thr308, Ser473, and pan-Akt polyclonals (New England BioLabs, Beverly, MA).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
STI571 Blocks SCF-mediated Kit Activation.
As is the case for other receptors in its class, ligand binding induces receptor dimerization, which in turn leads to autophosphorylation and an enhancement of the specific activity of the Kit kinase domain (18) . The H526 SCLC cell line expresses high levels of Kit, relatively low levels of SCF, and can grow in serum-free medium containing recombinant SCF (as the sole growth factor), which rapidly induces tyrosine phosphorylation and an increase in the specific enzymatic activity of Kit (23) . To determine the effect of STI571 on receptor activation, H526 cells made quiescent by overnight incubation in serum-free medium were pretreated with increasing concentrations of drug or DMSO vehicle for 30 min followed by the addition of SCF. Five min after the addition of SCF, cells were divided into two equal portions, and the degree of Kit activation was determined by assessing the extent of in vivo autophosphorylation by immunoblotting in one portion and in the other portion by directly measuring kinase activity in an IP-kinase assay. As illustrated in Fig. 1Citation , both the kinase assay and the assessment of in vivo tyrosine phosphorylation revealed an IC50 of 0.2 and 0.1 µM, respectively, in good agreement with previous studies on the highly related PDGFR, as well as the originally intended target, Bcr-Abl (9 , 12) . The residual kinase activity seen at high drug concentrations may be attributable to a small degree of binding reversibility during the IP and kinase reaction, both performed in the absence of additional drug.



View larger version (49K):
[in this window]
[in a new window]
  		Fig. 1. STI571 efficiently inhibited SCF-mediated Kit activation. H526 cells were serum-starved overnight and then either pretreated with DMSO vehicle or increasing concentrations STI571 for 30 min. The cells were then either left unstimulated or stimulated with 100 ng/ml SCF for 5 min, as indicated. Kit was then immunoprecipitated, and the degree of SCF-stimulated activation was analyzed by immune complex kinase assay and autoradiography (top panel) or antiphosphotyrosine Western blotting (middle panel). The Western blot was stripped and restained for Kit (lower panel). The lane labeled IgG represents a mock IP using nonimmune mouse IgG. IC50s were calculated by densitometry; data are representative of a minimum of two replicates of each assay.

 
STI571 Selectively Inhibits SCF-mediated Growth.
To determine the effect of STI571 on SCF-mediated growth, H526 cells were incubated in serum-free medium containing SCF, and increasing concentrations of drug and growth were measured at the end of 3 days using the MTT dye reduction assay. IGF-1-mediated growth was also assayed in the same fashion to determine the specificity of the drug. As illustrated in Fig. 2Citation , SCF-mediated growth was inhibited in a dose-dependent fashion with an IC50 of ~0.3 µM, with complete inhibition obtained at 1 µM. The average IC50 for three independent determinations was 0.8 ± 0.6 µM. Growth inhibition by STI571 clearly paralleled its inhibition of Kit kinase activity (Fig. 1)Citation . IGF-1-mediated growth was only modestly inhibited at 1 µM, but significant growth inhibition was seen at 10 µM. At this concentration, however, a large proportion of cells in the SCF-treated cultures underwent cell death, presumably by apoptosis as previously demonstrated for cells treated with AG 1296 (23) .



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2. STI571 selectively inhibited SCF-mediated growth. H526 cells were incubated in serum-free medium overnight and then left unstimulated (NS) or stimulated with saturating concentrations of SCF (100 ng/ml) or IGF-1 (20 ng/ml). These values represent twice the average growth factor concentration needed to produce a maximal growth response. Increasing concentrations of STI571 were added 30 min before the growth factors. Cell growth was assessed using the MTT colorimetric dye reduction method, which involved measuring the change in absorbance over 72 h. Data are representative of three individual experiments; bars, SD from the mean of eight replicate wells.

 
STI571 Inhibits Serum-stimulated Growth of a Panel of SCLC Cell Lines.
The above experiments demonstrate that STI571 selectively blocked growth of a SCLC cell line dependent on SCF as the only exogenous growth factor. However, to be clinically relevant, growth inhibition should extend to growth in the presence of a complex mix of growth factors, such as found in serum. To determine whether the drug could inhibit growth under these circumstances, a panel of six representative cell lines was incubated in medium containing 10% FCS, and increasing concentrations of STI571 and growth were measured over 72 h by MTT assay. All cell lines used coexpress SCF and Kit to some degree, with the exception of H146, which expresses high levels of SCF but not Kit (20) . Three of the cell lines (H146, H432, and H510) were derived from patients previously treated with chemotherapy, and three were derived from previously untreated patients (20 , 25) . One cell line, H510, showed no response to concentrations of STI571 up to 10 µM (data not shown); this is consistent with the lack of response this cell line displayed to another Kit inhibitor, AG 1296 (23) . The other five cell lines showed a dose-dependent decline in growth as illustrated in Fig. 3Citation . For these cell lines, growth inhibition at 10 µM STI571 was between 50 and 90%; the average IC50 for the five responsive cell lines was ~5 µM. Of note, H146, the only one of the six cell lines that does not express Kit, had an intermediate sensitivity to the drug, suggesting that, in addition to inhibiting Kit, the drug must block other targets necessary for SCLC growth. This point is further illustrated by the response of H526, which despite its sensitivity to low concentration of the drug when grown in SCF (Fig. 2)Citation , only showed 20–30% growth inhibition in serum-containing medium until a concentration of 10 µM was reached. It is likely that at this concentration, Kit is not the only affected target, as suggested by the inhibition of IGF-1-mediated growth at 10 µM STI571 (Fig. 2)Citation .



View larger version (31K):
[in this window]
[in a new window]
  		Fig. 3. STI571 inhibited growth of SCLC in serum-containing medium. Six representative cell lines were incubated in serum-containing medium for 72 h in the presence of increasing concentrations of STI571, and growth was measured by MTT assay; data on H510 were not illustrated because no significant growth inhibition was observed. The data were expressed as the percentage of growth at the indicated STI571 concentration relative to the DMSO vehicle control. Data are representative of three individual experiments; bars, SD from the mean of eight replicate wells.

 
Surprisingly, despite the decreased growth of cells treated with STI571 noted by MTT assay, no increase in the appearance of morphologically apoptotic cells over controls was observed in any of the treated cell lines, suggesting a cytostatic mechanism of action. This was opposed to the cell death observed when cells were treated while growing in medium containing SCF as the sole growth factor (Fig. 2)Citation . Because it is important to understand whether the drug mediates its effect through cytotoxic or cytostatic mechanisms, we directly assayed for the induction of apoptosis. First, we sought to confirm that the cell death we observed in serum-free medium containing SCF was attributable to apoptosis. H526 cells were exposed to STI571 or DMSO vehicle for 48 h in SCF medium, and apoptosis was assayed using a flow cytometric TUNEL assay. Fig. 4Citation A illustrates the marked increase in terminal deoxynucleotidyl transferase labeling of cells treated with STI571, indicative of DNA strand breakage and apoptosis. H526 cells exposed to STI571 in serum-containing medium were also analyzed using the flow cytometric TUNEL assay. No difference in the curves generated from vehicle and STI571-treated cells were noted. However, because of enhanced cell aggregation when grown in serum, the curves were complex and harder to interpret (data not shown). We therefore switched to an alternative assay that measured the activation of caspase-3, a critical mediator of apoptosis. As illustrated in Fig. 4Citation B, etoposide efficiently activated caspase-3 in all three cell lines tested but STI571 did not produce a statistically significant increase in caspase-3 in any of the cell lines tested. These observations are consistent with the lack of morphological evidence for apoptosis in STI571-treated cells grown in serum.



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 4. STI571 induced apoptosis of cells incubated in serum-free medium containing SCF but not of cells incubated in medium containing 10% FCS. A, H526 cells were incubated in serum-free medium containing 100 ng/ml SCF in the presence of either 5 µM STI571 (dotted curve) or DMSO vehicle (solid curve). After 48 h, a TUNEL assay was performed using fluorescently tagged dUTP and analyzed by flow cytometry. Similar results were obtained using 1 and 10 µM STI571. B, H526, H146, and H209 cells were incubated in medium containing 10% FCS and 10 µM STI571, 25 µM etoposide, or DMSO vehicle. After 48 h, caspase-3 activity was analyzed colorimetrically using 500 µg of cellular lysate; specific activity was calculated by comparison to p-nitroaniline standards. Bars, SD of duplicate determinations. Data are representative of three independent experiments.

 
On the basis of the above evidence, it appeared that STI571 mediated its growth inhibition in serum-containing medium through cytostatic mechanisms. To confirm this impression, the thymidine incorporation of cells treated with 10 µM STI571 for 24 h in serum-containing medium was determined; Fig. 5Citation illustrates representative results for the WBA and H146 cell lines. Tritiated thymidine incorporation decreased by ~50%, correlating well with results obtained in the MTT assay (Fig. 3)Citation and therefore indicating that STI571 acts predominantly by slowing proliferation in the presence of serum.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 5. STI571 inhibited tritiated thymidine incorporation. The WBA and H146 cell lines were incubated in complete medium containing 10 µM STI571 or an equal volume of DMSO (control) for 24 h, at which point tritiated thymidine was added to the medium. The incubation was continued for an additional 18 h at which time incorporation into labeled DNA was determined by liquid scintillation counting. Bars, SD from the mean of seven replicate wells.

 
STI571 Blocks Both SCF-Mediated MAP Kinase and Akt Activation.
To confirm that STI571 blocked downstream signal transduction from Kit and to develop some insight into the reasons for its cytotoxic effect on cells grown in SCF versus its cytostatic effect on cells grown in serum, we studied the effect of the drug on activation of MAP kinase and Akt, which lies downstream of phosphatidylinositol-3 kinase. Activation of these signal transduction proteins was studied by Western blotting using phospho-specific antibodies. As illustrated in Fig. 6Citation , the addition of SCF to quiescent H526 cells resulted in a potent activation of both MAP kinase and Akt that, as expected, was completely inhibited by pretreatment with 10 µM STI571. IGF-1 produced a weak activation of MAP kinase and a potent activation of Akt, which were unaffected by the presence of STI571. The addition of 10% FCS to quiescent cells produced an intermediate activation of MAP kinase, which was unaffected by the presence of the drug; no FCS-induced activation of Akt was seen in three replicate experiments. These experiments suggest that persistent activation of MAP kinase could be partially responsible for the lack of apoptosis of STI571-treated H526 cells when grown in FCS.



View larger version (54K):
[in this window]
[in a new window]
  		Fig. 6. STI571 blocked SCF-mediated MAP kinase and Akt activation. H526 cells were made quiescent by incubation in serum-free medium overnight. They were then preincubated for 30 min in either 10 µM STI571 or vehicle and then left unstimulated or stimulated with either 100 ng/ml SCF, 20 ng/ml IGF-1, or 10% FCS. After a 10-min incubation, whole cell lysates were analyzed by Western blotting with phospho-specific and pan Erk (top) and Akt (bottom) antibodies. Data are representative of three independent experiments.

 
STI571 Fails to Synergize with Carboplatinum.
It has been demonstrated that treatment of tumors expressing epidermal growth factor family receptors with blocking antibodies sensitizes the tumor cells to the effects of cis-platinum both in vitro and in vivo (28, 29, 30) . This observation could indicate a specific property of epidermal growth factor family receptors, of the antibodies used, or a general phenomenon relating to the interaction between the chemotherapeutic agent and blockade of necessary receptor tyrosine kinases. Because platinum compounds are an integral part of present chemotherapeutic regimens for SCLC (31 , 32) , we decided to determine whether STI571 would sensitize SCLC cell lines to the cytotoxic effects of carboplatinum, which was chosen because of its better aqueous solubility compared to cis-platinum. Cells were incubated in the continuous presence of increasing concentrations of carboplatinum in the presence of 5 µM STI571. The 5-µM concentration was chosen because it was the average IC50, as well as a potentially achievable serum concentration based on preliminary results of the ongoing Phase I trial (33) . The degree of growth inhibition relative to control cells incubated in the presence of carboplatinum alone was determined after 72 h by MTT assay. Three cell lines were chosen for study based on their varying sensitivity to carboplatinum, with IC50s ranging from <0.1 µg/ml to 5 µg/ml, and their varying sensitivity to STI571. As illustrated in Fig. 7Citation , STI571 failed to synergize with the cytotoxic effects of carboplatinum in any of these three cell lines; a fourth cell line (WBA) also showed no synergy (data not shown). On the contrary, in experiments using H526, there appeared to be a mild but reproducible protective effect in the presence of the kinase inhibitor, especially at high carboplatinum concentrations. In addition to carboplatinum, etoposide, the other integral component of SCLC chemotherapy regimens, was also tested in combination with STI571; no enhanced cytotoxicity over that produced by etoposide (1–10 µM) alone could be demonstrated for the combination using H526, WBA, or H432 cell lines (data not shown).



View larger version (36K):
[in this window]
[in a new window]
  		Fig. 7. STI571 did not synergize with the cytotoxic effects of carboplatinum. H432, H209, and H526 cells were incubated in serum-containing medium with increasing concentrations of carboplatinum in the presence or absence of 5 µM STI571. Growth was measured by MTT assay over a period of 72 h; an increase in absorbance of 100% indicates a doubling of viable cell number, and a decrease of 100% indicates complete death of the initial cell population. Data are representative of at least two individual experiments; bars, SD from the mean of eight replicate wells.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We have demonstrated that STI571 efficiently inhibits SCF-mediated Kit activation (in serum-free medium) at concentrations similar to those that inhibit both Bcr-Abl and the PDGFR in cellular assays, with an IC50 in the 0.1–0.5 µM range (9 , 12) . This observation likely reflects the related nature of the ATP-binding sites of these three kinases because the drug is competitive for ATP binding (9) . The inhibition of SCF-mediated SCLC growth closely parallels inhibition of Kit kinase activity, with complete inhibition of H526 growth occurring at 1 µM. The drug was clearly selective because the same degree of growth inhibition was not obtained in IGF-1-containing medium until a 10-fold higher concentration was attained.

The selectivity seen in serum-free medium supplemented with single growth factors was apparently reduced in serum-containing medium. The IC50 for H146, which does not express Kit, was 5 µM, which was approximately the average for all of the sensitive cell lines combined. This observation suggests two conclusions. The first is that the contribution of Kit activation to growth of SCLC cell lines in medium containing 10% FCS is likely to be relatively limited because the IC50 in serum is far higher than the drug concentration needed to completely block growth mediated by saturating concentrations of SCF. A potentially confounding factor affecting this conclusion could be binding or inactivation of the drug by some component of serum. We feel that this is not likely to be an important factor because the growth inhibition of H526 in serum relatively closely paralleled the growth inhibition seen in serum-free medium containing IGF-1, suggesting that drug inactivation by serum does not significantly contribute to the higher IC50. Response to the drug was fairly consistent, despite distinct biological properties of the cell lines used (25) and despite variation in the sensitivity to carboplatinum (Fig. 7)Citation and etoposide. It is worth pointing out, however, that there appears to be some correlation with the degree of endogenous SCF expression and the sensitivity to STI571. Both the H432 and H209 cell lines express high levels of both SCF and Kit (20) and are the most sensitive to drug in serum, whereas H526, which expresses very high levels of Kit and little SCF, is the least sensitive. However, expression levels of SCF cannot explain the growth inhibition of H146 because it expresses no Kit. Therefore, it is likely that there is an additional drug target that is partially responsible for SCLC growth inhibition by STI571, especially at drug concentrations that exceed 2.5 µM. The identity of this hypothetical target is not known at this time, but given the in vitro selectivity of this compound for a conserved ATP-binding pocket, it is possible that the additional target is a tyrosine kinase related to the PDGFR family or c-ABL. The fact that the relative sensitivity of a panel of cell lines to STI571 parallels their sensitivity to the quinoxaline tyrphostin AG1296 (23) , an inhibitor of PDGFR and Kit but not Abl (34) , suggests that unidentified drug target may be more likely related to the PDGFR family. In addition, the similar pattern of growth inhibition observed using two tyrosine kinase inhibitors having dissimilar chemical structures suggests that the inhibition is attributable to their ability to inhibit Kit and related kinases. One important question that arises is whether the existence of additional targets of STI571 affects its potential as a therapeutic agent for SCLC. Because the toxicity of the drug at concentrations up to 10 µM for nontransformed cells in culture was nonexistent (10 , 12) or limited (9 , 13) and limited animal studies produced no detectable toxicity (15) , it is possible that the additional drug target is selectively activated in SCLC. The existence of an additional drug target may be an advantage because it provides the potential for inhibition of the 25–30% of SCLCs, represented by the H146 cell line, which do not express Kit. If further in vivo toxicity studies confirm little toxicity at concentrations that inhibit SCLC growth, there could be an exploitable therapeutic index even if the effect of STI571 cannot entirely be attributable to inhibition of Kit.

SCLC is generally thought of as a highly chemotherapy-responsive disease, with a variety of multidrug combinations producing response rates of >80%, with a third or more being complete responses (31 , 32) . Despite this high response rate, virtually all extensive stage patients and 75–80% of limited stage patients (treated with combined modality therapy) succumb to the disease within ~2 years. Increasing the dose of standard chemotherapeutic agents has produced increased toxicity without increasing response or survival (32 , 35) . Despite the relative paucity of long-term survivors, chemotherapy has made a major impact on the treatment of this disease, with present regimens improving stage-specific survival at least 3–4 fold, in addition to concomitant improvements in quality of life (31) . Thus, novel therapeutic approaches that prolong overall survival with minimal toxicity, even if they do not increase the percentage of long-term survivors, could be of significant benefit in this disease. STI571 could fall into this category based on its ability to be p.o.-dosed and its limited toxicity for nontransformed cells seen in previous studies at concentrations of drug we have shown to significantly inhibit SCLC growth. We had hoped that the effects of STI571 would synergize with the effects of standard chemotherapeutic agents, such as carboplatinum based on previous studies demonstrating enhanced platinum sensitivity of EGFR family-expressing tumors treated with blocking monoclonal antibodies (5) or a small molecule antagonist (36) . This turned out not to be the case, at least for a schedule using continuous coadministration of both drugs. The different effects of the receptor tyrosine kinase inhibitors on platinum sensitivity could be related to differences between the biological effects of receptor tyrosine kinase subclasses, between SCLC and the predominantly breast and non-SCLC cell lines used in the EGFR studies, or between the specific agents themselves.

STI571 appears to be cytostatic for SCLC cells grown in FCS based on its ability to inhibit growth without an increase in apoptosis. This is in contrast to the cytotoxicity secondary to apoptosis seen when SCF was the only exogenous growth factor provided (Fig. 2Citation ; Fig. 4Citation A). However, it is unlikely that FCS accurately mimics all relevant in vivo situations. For example, for SCLC to recur after a chemotherapy-induced complete remission, the tumor cells must repopulate from relatively few cells originally located in a mostly necrotic tumor mass or alternatively from micrometastases in sanctuary sites such as the central nervous system. In these locations it could be hypothesized that autocrine growth stimulation, such as provided by coexpression of SCF and Kit, could be relatively more important than in environments rich in growth factors. Therefore, inhibition of autocrine growth with agents such as STI571 could potentially block recurrence after a chemotherapy-induced remission; however, even if the time to a clinically symptomatic recurrence was delayed by slowing tumor growth, this could have significant impact on survival and quality of life. The ability to p.o. dose the drug, along with the minimal toxicity seen in preliminary studies, suggests that it could be useful in such a setting. Therefore, based on these hypotheses and the demonstration that STI571 significantly inhibits SCLC growth, we believe further studies of STI571 in nude mouse SCLC xenograft models are warranted. We also believe that it would be reasonable to include recurrent SCLC patients in expansions of present ongoing Phase I clinical trials of STI571 (33) .


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by a Merit Review Award from the Department of Veterans Affairs. Back

2 To whom requests for reprints should be addressed, at Richmond Veterans Affairs Medical Center (111K), 1201 Broad Rock Boulevard, Richmond, VA 23249. Phone: (804) 675-5446; Fax: (804) 675-5447; E-mail: gkrystal{at}hsc.vcu.edu Back

3 The abbreviations used are: EGFR, epidermal growth factor receptor; SCLC, small cell lung cancer; SCF, stem cell factor; CML, chronic myelogenous leukemia; IGF-1, insulin-like growth factor-1; PDGFR, platelet-derived growth factor receptor; IP, immunoprecipitation; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; MAP, mitogen-activated protein. Back

4 E. Buchdunger, unpublished observations. Back

Received 11/22/99; revised 2/ 7/00; accepted 2/16/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hunter T. Oncoprotein networks. Cell, 88: 333-346, 1997.[CrossRef][Medline]
  2. Marshall C. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80: 179-185, 1995.[CrossRef][Medline]
  3. Gibbs J., Oliff A. Pharmaceutical research in molecular oncology. Cell, 79: 193-198, 1994.[CrossRef][Medline]
  4. Levitski A., Gazit A. Tyrosine kinase inhibition; an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.[Abstract/Free Full Text]
  5. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.[Abstract/Free Full Text]
  6. Fry D. W., Kraker A. J., McMichael A., Ambroso L. A., Nelson J. M., Leopold W. R., Conners R. W., Bridges A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 269: 1093-1095, 1994.
  7. Buchdunger E., Mett H., Trinks U., Regenass U., Muller M., Meyer T., Beilstein P., Wirz B., Schneider P., Traxler P., Lydon N. 4,5-bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.[Abstract]
  8. Strawn L. M., McMahon G., App H., Schreck R., Kuchler W. R., Longhi M. P., Hui T. H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirth K. P., Shawver L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.[Abstract/Free Full Text]
  9. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B. J., Lydon N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.[Abstract/Free Full Text]
  10. Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmermann J., Lydon N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.[CrossRef][Medline]
  11. Faderl S., Talpaz M., Estrov Z., O’Brien S., Kurzrock R., Kantarjian H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-72, 1999.[Free Full Text]
  12. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N. B., Gilliland D. G., Druker B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997.[Abstract/Free Full Text]
  13. Deininger M. W., Goldman J. M., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997.[Abstract/Free Full Text]
  14. Beran M., Cao X., Estrov Z., Jeha S., Jin G., O’Brien S., Talpaz M., Arlinghaus R. B., Lydon N. B., Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res., 4: 1661-1672, 1998.[Abstract]
  15. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst., 91: 163-8, 1999.[Abstract/Free Full Text]
  16. Sauseville E. A. A Bcr/Abl antagonist for chronic myelogenous leukemia: a promising path for progress emerges. J. Natl. Cancer Inst., 91: 102-103, 1999.[Free Full Text]
  17. Yarden Y., Kuang W. J., Yang-Feng T., Coussens L., Munemitsu S., Dull T. J., Chen E., Schlessinger J., Francke U., Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 6: 3341-3351, 1987.[Medline]
  18. Lev S., Blechman J. M., Givol D., Yarden Y. Steel factor and c-kit proto-oncogene: genetic lessons in signal transduction. Crit. Rev. Oncog., 5: 141-168, 1994.[Medline]
  19. Hibi K., Takahashi T., Sekido Y., Ueda R., Hida T., Ariyoshi Y., Takagi H., Takahashi T. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991.[Medline]
  20. Plummer H., III, Catlett J., Leftwich J., Armstrong B., Carlson P., Huff T., Krystal G. c-myc expression correlates with suppression of c-kit proto-oncogene expression in small cell lung cancer cell lines. Cancer Res., 53: 4337-4342, 1993.[Abstract/Free Full Text]
  21. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br. J. Cancer, 67: 37-46, 1993.[Medline]
  22. Sekido Y., Takahashi T., Ueda R., Takahashi M., Suzuki H., Nishida K., Tsukamoto T., Hida T., Shimokata K., Zsebo K. M., Takahashi T. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit proto-oncogene. Cancer Res., 53: 1709-1714, 1993.[Abstract/Free Full Text]
  23. Krystal G. W., Carlson P., Litz J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res., 57: 2203-2208, 1997.[Abstract/Free Full Text]
  24. Krystal G. W., Hines S., Organ C. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.[Abstract/Free Full Text]
  25. Carney D. N., Gazdar A. F., Bepler G., Guccion J. G., Marangos P. J., Moody T. W., Zweig M. H., Minna J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res., 45: 2913-2923, 1985.[Abstract/Free Full Text]
  26. Carmichael J., DeGraf W. G., Gazdar A. D., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.[Abstract/Free Full Text]
  27. Gavrieli Y., Sherman Y., Ben-Sassoon S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragments. J. Cell Biol., 119: 493-501, 1992.[Abstract/Free Full Text]
  28. Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.[Abstract/Free Full Text]
  29. Fan Z., Baselga J., Masui H., Mendelsohn J. Anti-tumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4322-4328, 1993.[Abstract/Free Full Text]
  30. Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.[Abstract]
  31. Ihde D., Pass H., Glatstein E. Small cell lung cancer DeVita V. Hellman S. Rosenberg S. eds. . Cancer: Principles & Practice of Oncology, : 911-949, Lippincott Philadelphia 1997.
  32. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol., 14: 658-665, 1996.[Free Full Text]
  33. Drucker B. J., Sawyer C. L., Tolpaz M., Resta D., Ping B., Ford J. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Blood, 92(Suppl.1): 1034a 1998.
  34. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C-H., Waltenberger J., Bohmer F., Levitski A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res., 54: 6106-6114, 1994.[Abstract/Free Full Text]
  35. Ihde D. C., Mulshine J. L., Kramer B. S., Steinberg S. M., Linnoila R. I., Gazdar A. F., Edison M., Phelps R. M., Lesar M., Phares J. C., Grayson J., Minna J. D., Johnson B. E. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol., 12: 2022-2034, 1994.[Abstract/Free Full Text]
  36. Tsai C. M., Levitzki A., Wu L. H., Chang K. T., Cheng C. C., Gazit A., Perng R. P. Enhancement of chemosensitivity by tyrphostin AG 825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res., 56: 1068-1074, 1996.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Reproductive SciencesHome page
R. P. Rocconi, K. S. Matthews, K. J. Kimball, M. G. Conner, A. C. Baker, and M. N. Barnes
Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors
Reproductive Sciences, September 1, 2008; 15(7): 673 - 677.
[Abstract] [PDF]

Home page
 Mol Cancer ResHome page
V. Gioni, T. Karampinas, G. Voutsinas, A. E. Roussidis, S. Papadopoulos, N. K. Karamanos, and D. Kletsas
Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts
Mol. Cancer Res., May 1, 2008; 6(5): 706 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al.
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
Cancer Res., January 15, 2008; 68(2): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
S. V. Sharma and J. Settleman
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Genes & Dev., December 15, 2007; 21(24): 3214 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
P. Bertino, C. Porta, D. Barbone, S. Germano, S. Busacca, S. Pinato, G. Tassi, R. Favoni, G. Gaudino, and L. Mutti
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
Thorax, August 1, 2007; 62(8): 690 - 695.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi
Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment
Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Litz and G. W. Krystal
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1{alpha} activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1415 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al.
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
Cancer Res., January 15, 2006; 66(2): 1015 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. Rao, N. Kremenevskaja, R. von Wasielewski, V. Jakubcakova, S. Kant, J. Resch, and G. Brabant
Wnt/{beta}-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 159 - 168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al.
Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung
J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
Ann. Onc., November 1, 2005; 16(11): 1811 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Tsurutani, K. A. West, J. Sayyah, J. J. Gills, and P. A. Dennis
Inhibition of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-Mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy
Cancer Res., September 15, 2005; 65(18): 8423 - 8432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Vidal, S. Wells, A. Ryan, and R. Cagan
ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma
Cancer Res., May 1, 2005; 65(9): 3538 - 3541.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Deininger, E. Buchdunger, and B. J. Druker
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Blood, April 1, 2005; 105(7): 2640 - 2653.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Basciani, M. Brama, S. Mariani, G. De Luca, M. Arizzi, L. Vesci, C. Pisano, S. Dolci, G. Spera, and L. Gnessi
Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity
Cancer Res., March 1, 2005; 65(5): 1897 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal
The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy
Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Stem Cells, January 1, 2005; 23(1): 16 - 43.
[Abstract] [Full Text] [PDF]